Clinical trial
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of…
NCT00485407 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00485407 |
|---|---|
| Title | Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine |
| Official title | Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine Hydrochloride |
| Enrollment | 377 |
| Start date | Jul 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Jun 13, 2007 |
| Last update posted | Nov 1, 2007 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: